UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol

First Page		Document Content
Date: 2016-01-20 09:39:34 Medicine Clinical medicine Immunology Immunosuppressants RTT Biotechnology Autoimmune diseases Arthritis Certolizumab pegol TNF inhibitor UCB Anakinra		UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol Add to Reading List Source URL: www.ucb-usa.com Download Document from Source Website File Size: 539,51 KB Share Document on Facebook

	Biotechnology, BS "DBEFNJD.BQ 5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT DocID: 1xTqy - View Document
	PDF Document DocID: 1wroO - View Document
	Building A Better Mousetrap: Patenting Biotechnology In The European Community DocID: 1vr7C - View Document
	BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod DocID: 1vq6b - View Document
	Biotechnology Consultation Agency Response Letter BNF DocID: 1vpUZ - View Document